Lisinopril

Basic Information


CAS ID: 76547-98-3
Molecular Formula: C21H31N3O5
Molecular Weight: 405.5 g/mol
Monoisotopic Mass: 405.2264 g/mol
Class: Small Molecule
Natural Product: No
Other Names: QBRELIS | LISINOPRIL | CARACE | ZESTRIL | Lisinopril hydrate | ACEMIN | LISOPRESS | MK-521 | PRINIVIL | Zestril
Analysis: Drug repositioning mechanism analysis

NH2 NH O HO O N O HO


Compound Structure and Identifier


InChI: InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1 See All
InChI Key: RLAWWYSOJDYHDC-BZSNNMDCSA-N
Smiles: NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N2CCC[C@H]2C(=O)O See All
Molfile: Download


Related Target


Target ID Name Interaction
T0213 Angiotensin-converting enzyme inhibitor

Related Fibrosis Property


Reference Record 1

PubMed ID 20719975 Target ID T0213
Uniprot ID Angiotensin-converting enzyme Name Angiotensin-converting enzyme
Model rat Fibrosis Disease Renal fibrosis
Process I attenue inflammation
Process II
Process III prevenet collagen deposition
Mechanism

Reference Record 2

PubMed ID 25945342 Target ID T0213
Uniprot ID Angiotensin-converting enzyme Name Angiotensin-converting enzyme
Model rat Fibrosis Disease Renal fibrosis
Process I
Process II
Process III prevenet collagen deposition
Mechanism

Trial Record 1

ClinicalTrial ID NCT01535235 Disease Fibrosis
Phase Phase 4 Status Completed
First Received February 17, 2012 Last Verified June 16, 2016
Sponsor University of California, San Francisco

Trial Record 2

ClinicalTrial ID NCT02682459 Disease Renal fibrosis
Phase Phase 2 Status Recruiting
First Received February 15, 2016 Last Verified April 6, 2018
Sponsor Monia Lorini

Related Link


PubChem: 11865407
ChEMBL: CHEMBL1237